Company Research Report on CrossBridge Bio
Company Overview
Name
CrossBridge Bio
Mission
CrossBridge Bio aims to overcome the shortcomings seen with current Antibody-Drug Conjugates (ADCs) to deliver better therapeutics for patients, especially in cancer treatment.
Founded
No information is available
Founders
No information is available
Key People
- Michael Torres, Ph.D. - Co-Founder & Chief Executive Officer
- Abhishake Chhibber - Chief Operating Officer
- Daniel Pereira, Ph.D. - Chief Scientific Officer
- Morris Rosenberg, Ph.D. - Acting Chief Technology Officer
- Zhiqiang An, Ph.D. - Co-Founder & Scientific Advisory Board (SAB)
- Kyoji Tsuchikama, Ph.D. - Co-Founder & SAB
- Paolo Tarantino, M.D. - Clinical Advisor
- David Hong, M.D. - Clinical Advisor
- Patrick Crutcher, MSc - Board Member & Advisor
- Martin Dietrich, M.D., Ph.D. - Clinical Advisor
Headquarters
Texas Medical Center Innovation, 2450 Holcombe Blvd., Suite X, Houston, TX 77021
Number of Employees
No information is available
Revenue
No information is available
What is the Company Known For
CrossBridge Bio is known for its innovative technology platform for ADCs, which includes unique technologies such as EGCit Linkers, microbial transglutaminase (mTG) enabled conjugation, and synergistic antibody-payload pairings. Their focus is on improving the stability, effectiveness, and safety of ADCs for cancer therapeutics.
Products
Product Offerings
1. EGCit (GluGlyCit) Enzymatically Cleavable Linker
- High-Level Description: An advanced protease-cleavable linker for ADCs that offers enhanced stability and increased hydrophilicity.
- Key Features:
- Unparalleled stability against proteases
- Swift payload release within targeted cancer cells
- Minimized unintended tissue uptake, ADC aggregation, and rapid clearance
2. Enzymatic Conjugation of Branched Linkers
- High-Level Description: Uses microbial Transglutaminase (mTG) to conjugate branched linkers at precise sites on human IgG1, enabling dual payload ADCs.
- Key Features:
- Precise control over Drug-to-Antibody Ratio (DAR)
- Uniform ADC production
- Development of dual-payload ADCs for synergistic therapeutic effects
3. Synergistic Antibody-Payload Pairings
- High-Level Description: Integrated platform technology for combining diverse antibodies with various payload mechanisms.
- Key Features:
- Diverse antibody-payload combinations
- Optimal molecular properties and pharmacological actions
- First-in-class and best-in-class ADC solutions with superior safety profiles
Recent Developments
New Products and Features
- CBB-120: Next-generation Dual-Payload ADC for TROP-2+ Solid Tumors, supported by a $2.6M non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
New Partnerships
No information is available
Recent Publications
- May 15, 2024: CrossBridge Bio receives $2.6M funding for CBB-120.
- September 6, 2022: Publication on EGCit linkers enhancing ADCs' therapeutic index.
- May 24, 2022: Study on homogeneity of ADCs improving brain tumor treatment efficacy.
- June 10, 2021: Research on dual payload ADCs for breast tumor heterogeneity.
- February 15, 2021: Findings on small-molecule based bispecific ADCs.
- June 28, 2018: Study on glutamic acid-valine-citrulline linkers ensuring ADC stability.
Upcoming Events
- AACR Annual Meeting 2024: April 5-10, 2024, San Diego Convention Center
- ASCO Annual Meeting 2024: May 31 - June 4, 2024
For further inquiries:
Texas Medical Center Innovation
2450 Holcombe Blvd., Suite X, Houston, TX 77021
Email: info@crossbridgebio.com
LinkedIn: [CrossBridge Bio](#)
©2024 CrossBridge Bio. All Rights Reserved.
